Third Rock Thinks Its Model Reassures Investors In Difficult Times
Venture Firm Raised $1.1bn Fund VI, Its Largest Yet
New fund will include some later-stage investments in portfolio companies, in recognition of the currently tough environment for privately held biotechs.
You may also be interested in...
ARCH Venture Partners brought in $2.975bn for its latest fund to give additional long-term investors a place at the table as the VC firm creates, builds and supports new early-stage biotechnology start-ups.
Private Company Edition: While the tough state of financing for publicly traded drug developers continues, venture capital firms and private biopharma companies revealed billions of dollars in new VC funds and start-up financings, including $100m-plus mega-rounds for Tessa, Alladapt and ImCheck.
The mid-year meeting offered a chance to reflect on the tumultuous times and look at how the biopharma industry can weather the storm.